Literature DB >> 25122725

Mortality in patients with giant cell arteritis.

Bo Baslund1, Marie Helleberg2, Mikkel Faurschou2, Niels Obel2.   

Abstract

OBJECTIVE: The aim of this study was to examine whether GCA is associated with increased mortality.
METHODS: We conducted a nationwide population-based cohort study including all individuals who between 1993 and 2011 were registered in the Danish National Hospital Register and the Danish Pathology Register with a biopsy-proven diagnosis of GCA (n = 1787). Through the Danish Civil Registration System we identified a comparison cohort of 33 953 persons from the background population, individually matched on age and sex. Data on causes of death were obtained from the Danish Registry of Causes of Death. We used Poisson regression to determine mortality rate ratios as estimates of relative risk of death and specific causes of death.
RESULTS: Compared with the general population, the relative risk (RR) of death in patients diagnosed with GCA was 1.17 (95% CI 1.01, 1.36) and 1.22 (95% CI 1.05, 1.41) 0-2 years and >10 years after diagnosis, respectively, whereas we observed no increased mortality during the follow-up period of 2-10 years [RR 0.96 (95% CI 0.88, 1.05)]. The increased mortality during the first 2 years of follow-up was mainly due to diseases of the circulatory system, including aortic aneurisms.
CONCLUSION: GCA is associated with slightly increased early and late mortality.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  GCA; aortic aneurysm; cancer; cardiovascular disease; epidemiology; mortality

Mesh:

Year:  2014        PMID: 25122725     DOI: 10.1093/rheumatology/keu303

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  8 in total

Review 1.  Update on the management of giant cell arteritis.

Authors:  Janet Roberts; Alison Clifford
Journal:  Ther Adv Chronic Dis       Date:  2017-03-28       Impact factor: 5.091

2.  Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015.

Authors:  Cynthia S Crowson; Eric L Matteson
Journal:  Semin Arthritis Rheum       Date:  2017-04-07       Impact factor: 5.532

3.  Incidence, survival, and diagnostic trends in GCA across seven decades in a North American population-based cohort.

Authors:  Thomas D Garvey; Matthew J Koster; Cynthia S Crowson; Kenneth J Warrington
Journal:  Semin Arthritis Rheum       Date:  2021-09-27       Impact factor: 5.532

Review 4.  Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update.

Authors:  Gideon Nesher; Gabriel S Breuer
Journal:  Rambam Maimonides Med J       Date:  2016-10-31

5.  Does low risk of infections as a marker of effective immunity predict increased risk of subsequent giant cell arteritis or polymyalgia rheumatica? A Danish population-based case-control study.

Authors:  Clément Brault; Anders H Riis; Anil Mor; Pierre Duhaut; Reimar W Thomsen
Journal:  Clin Epidemiol       Date:  2018-10-16       Impact factor: 4.790

6.  Survival and death causes of patients with giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study.

Authors:  L K Brekke; B-T S Fevang; A P Diamantopoulos; J Assmus; E Esperø; C G Gjesdal
Journal:  Arthritis Res Ther       Date:  2019-06-25       Impact factor: 5.156

7.  The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population.

Authors:  Max Yates; Karly Graham; Richard Arthur Watts; Alexander James MacGregor
Journal:  BMC Musculoskelet Disord       Date:  2016-07-15       Impact factor: 2.362

8.  Can rheumatologists diagnose and manage Giant Cell Arteritis better than non-rheumatologists? The Maltese Experience.

Authors:  Erika Cefai; Marica Galea; Rebecca Galea; Andrew A Borg; Cecilia Mercieca
Journal:  Mediterr J Rheumatol       Date:  2017-09-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.